Clinical trialNCT06922591RecruitingPhase 1/PHASE2Interventional

Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

SponsorTango Therapeutics, Inc.Enrollment183Lung CancerMTAP DeletionNSCLCPDACPDAC - Pancreatic Ductal AdenocarcinomaPancreatic Cancer Metastatic+2 more conditions

View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Maxim Pimpkin, MD, PhD
Tango Therapeutics, Inc.
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

18 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Mayo Clinic Scottsdale
Scottsdale, Arizona, United States
Mitesh Borad, MD
Recruiting
Sarah Cannon Research Institute Denver
Denver, Colorado, United States
Gerald Falchook, MD, MS
Recruiting
Georgetown University Medical Center
Washington D.C., District of Columbia, United States
Marcus Noel, MD
Recruiting
Mayo Clinic Jacksonville
Jacksonville, Florida, United States
Hani Babiker, MD
Recruiting
Northwestern Memorial Hospital
Chicago, Illinois, United States
Chengwei Peng, MD
Recruiting
University of Indiana
Indianapolis, Indiana, United States
Anita Turk, MD
Recruiting
University of Iowa Health Care
Iowa City, Iowa, United States
Naomi Fei, MD, MS
Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Kimberly Perez, MD
Recruiting
Massachusetts General Hospital
Boston, Massachusetts, United States
Harshabad Singh, MD
Recruiting
Mayo Clinic Cancer Center
Rochester, Minnesota, United States
Kaushal Parikh, MD
Recruiting
Nebraska Cancer Specialists
Omaha, Nebraska, United States
Joel Michalski, MD, PhD
Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Eileen O'Reilly, MD
Recruiting
Nyu Langone Health
New York, New York, United States
Kristen Spencer, DO, MPH
Recruiting
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States
Shetal Patel, MD, PhD
Recruiting
University of Texas Md Anderson Cancer Center
Houston, Texas, United States
Jordi Rodon Ahnert, MD
Recruiting
Next Dallas
Irving, Texas, United States
Siraj Sen, MD
Recruiting
Huntsman Cancer Institute, University of Utah
Salt Lake City, Utah, United States
Vaia Florou, MD, MS
Recruiting
Next Oncology
Fairfax, Virginia, United States
Alexander Spira, MD, PhD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Daraxonrasib →ZoldonrasibVopimetostat →Gemcitabine →MFOLFIRINOX

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 May 2025
Primary completion: 30 Jun 2027
Completion: 31 Dec 2027
Last update posted: 14 May 2026
Registered enrollment: 183
Registry id: NCT06922591

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.